|Publication number||USRE32874 E|
|Application number||US 06/860,894|
|Publication date||Feb 21, 1989|
|Filing date||May 8, 1986|
|Priority date||Nov 1, 1982|
|Also published as||CA1216518A, CA1216518A1, DE3380112D1, EP0108588A2, EP0108588A3, EP0108588B1, US4447415|
|Publication number||06860894, 860894, US RE32874 E, US RE32874E, US-E-RE32874, USRE32874 E, USRE32874E|
|Inventors||Gail A. Rock, George A. Adams|
|Original Assignee||Gail A. Rock|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (19), Non-Patent Citations (53), Referenced by (63), Classifications (10), Legal Events (3)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This invention is concerned with a method for the storage of blood platelets in a plasma-free medium. Also described is a platelet concentrate obtained by this method.
Thrombocytopenia means low platelet counts in the circulatory system. Persons with this disease have a tendency to bleed as do hemophiliacs, except that the bleeding is usually from many small capillaries rather than from large vessels as in hemophilia. Such persons suffer small punctate hemorrhages throughout all the body tissues. The skin of such a person will exhibit many small, purplish blotches. Platelets are especially important for repair of minute breaks in capillaries and other small vessels. Platelets aglutinate to fill such ruptures without actually causing clots.
Normally, excessive bleeding does not occur until the number of platelets in the blood falls below a value of approximately 70,000 per cubic millimeter rather than the normal of 150,000 to 350,000.
At the present time, persons who have low platelet counts are supported by infusion of platelet concentrates. Platelet concentrates contain on average 6×1010 platelets suspended in a volume of 50-60 ml of plasma. Larger platelet concentrates can be obtained using apheresis machinery, in which case the concentration is in the range of 4×1011 and the plasma volume may reach 200-300 ml. Platelet concentrates can be kept for 3, 5 or even 7 days, depending on the type of bag and mode of rotation used.
There are generally speaking two types of blood collection and storage bags available. One type permits storage of platelets in plasma for up to 3 days while another type permits storage of platelets in plasma for up to 5 days and sometimes up to 7 days. The latter type is generally used for research purposes. In addition it should be noted that platelet storage bags must not contain the plasticizer di-2-ethyl-hexylphthalate and they should be highly permeable. While stored, all bags are subjected to rotation on a continuous basis which can be rotational about a transverse axis or horizontal and reciprocal or horizontal and circular.
The present inventors have developed a method whereby platelets can be stored in a medium other than plasma while still retaining the functional characteristics of platelets stored in plasma. The technique involves centrifugation of the plasma to obtain a platelet pellet, removal of the supernatant plasma, and subsequent resuspension of the platelet pellet in a balanced salt medium.
Thus, the present invention provides a method for the preparation of a platelet concentrate which comprises centrifuging plasma to obtain a platelet pellet, removing supernatant plasma and resuspending the platelet pellet in a balanced salt medium.
The plasma can be derived from freshly collected while blood or may be collected using apheresis machinery, i.e. apheresis platelets. The blood or plasma is preferably collected from humans.
The balanced salt medium or isotonic solution is designed to provide the basic nutrients required for platelet support during storage and, as well, to enhance the environment above that obtained under plasma (physiological) conditions. More specifically, the isotonic solution or balanced salt medium comprises a conventional, physiologically tolerable isotonic solution to which various additional additives may be added to enhance platelet stability.
Examples of conventional balanced salt mediums or isotonic solutions which can be used for this purpose are Spinner salt solution (Eagle H, Science, 130:432 (1959)), Tyrode's (Tyrode, M. V., Arch. Intern. Pharmacodyn., 20:205 (1910)), Seligmann balanced salt solution (formula below), Earle's balanced salt solutions (Natl. Cancer. Inst. 4:167 (1943)), Dulbecco's phosphate buffered saline (J. Exp. Med., 98:167 (1954)), Hanks' balanced salt solutions (Proc. Soc. Exp. Biol. Med., 71:196 (1949)), modification-National Institutes of Health) Gey's balanced salt solutions (Amer. J. of Cancer, 27:55 (1936)), Puck's saline (Puck, T. T., Cieciura, S. J. and Robinson, A. J. Exp. Med., 108:945 (1958)).
The formula for Seligmann balanced salt solution is as follows:
______________________________________Component mg/L______________________________________NaCl 7650.00KCl 200.00NaCO2.CH3 1500.00NaH2 PO4.H2 O 50.00KH2 PO4 100.00D-Glucose 1000.00NaHCO3 700.00Ascorbic Acid 3.00______________________________________
There are several advantages to using a balanced salt solution in place of plasma and these are as follows. The plasma can be recovered and can be used for other purposes involving protein fractionation or transfusion to patients. Plasma is an expensive commodity and generally in short supply. Replacement of the plasma as a supernatant for platelet storage would result in considerable saving of plasma (estimated 14,000 liters in Canada alone in 1982) throughout the world.
Another advantage is the possibility of enhancing the storage environment above that generally found for plasma. Platelets are collected into an anticoagulant solution whose pH and biochemical constituents are chosen to enhance red cell preservation and which therefore may not be of optimal composition for platelet storage.
Beside the economic advantages, there are considerable theoretical medical advantages to removal of plasma and resuspension of platelets in a plasma free medium:
i. Removal of plasma components that are potentially harmful to platelets such as glycolytic and proteolytic enzymes that remove membrane glycoproteins and thus cause premature clearance from the circulation;
ii. Reduce the risk of exposure to infectious agent;
iii. Reduced risk of immediate and delayed allergic responses of recipients;
iv. Greater control over environmental conditions, especially pH, ion concentration and volume;
v. Reduced variations in platelet concentrates that would enhance the confidence of physicians in platelet concentrates perhaps leading to therapeutic regimes requiring fewer platelet concentrates per treatment; and
vi. The addition of agents to the storage medium may further improve platelet function after storage or prolong the storage life of platelets.
The agents which can be added to the storage medium can include one or more of the following. Nutrients may be added to the medium, and may be selected from fructose and other sugars, adenine or acetyl CoA. These nutrients are substrates for the glycolytic or proteolytic enzymes on the platelet surface and prevent these enzymes from altering the platelet surface.
Another approach is to inhibit the above and other enzymes with reversible inhibitors that are diluted upon infusion into the circulatory system and hence no longer inhibitory. Examples of these compounds are indomethacin, quinacrine or vitamin E, all of which inhibit platelet activation during storage and perhaps increase storage life.
Yet another method to control platelet activation during storage is to raise cyclic adenosine monophosphate with exogenous prostaglandins E1, D2 or I2 which again have a short half-life in vivo and reversible effects on platelets.
Finally, the artificial medium can be buffered by addition to the medium of a number of agents all of which can safely be infused into patients. These include phosphate and the amino acids: histidine, cysteine, tyrosine, lysine or arginine. These amino acids have the ability to buffer at an alkaline pH of 9 while phosphate precipitates at this pH.
Thus, in summary the isotonic solution may contain nutrients to improve the storage life of the platelets, reversible inhibitors for platelet activation, substances to raise cyclic adenosine monophosphate levels and which have reversible effects on platelets, and buffering agents which can be safely infused into patients. Generally these additives are used in physiological salt concentrations.
By the present method, the storage of platelet concentrates in a plasma free medium can be effected for at least 72 hours and results can be obtained which are similar to or better than those currently found using standard conditions of storage in plasma.
In another aspect, this invention provides a platelet concentrate in a plasma-free medium, which medium is a balanced salt medium which is an isotonic solution. The solution may be modified with the previously described agents. The present platelet concentrates can be stored for the same amount of time as presently available plasma concentrates can be stored. Further the platelet concentrates in the non-plasma medium are about the same as for the plasma medium, that is, about 109 ml or 1012 /L.
The following examples are used to illustrate the present invention. All parts and percentages are by weight unless otherwise specified.
Two series of experiments were carried out to show the effects of storing platelets in a non-plasma medium. The first series (A) uses extraction and a washing step to remove plasma from platelets prior to final suspension in a Tyrode's solution. The second series (B) uses only extraction of plasma and final suspension in a modified Tyrode's solution containing either extra phosphate buffer or histidine buffer.
Preparation of Platelet Concentrates: Platelet concentrates were prepared by acidification of a pool of platelet-rich plasma using 35 ml acid-citrate-dextrose anticoagulant to 230 ml of platelet-rich plasma, to yield a final pH of 6.4. This lower pH allows immediate resuspension of platelets concentrated by the normal centrifugation procedure of 3000 g for 5.5 minutes. The plasma was extracted and the platelets resuspended in a washing solution containing 0.5 mM EDTA in calcium and magnesium-free Tyrode's buffer, pH 6.4. After centrifugation at 3000 g for 5.5 minutes and extraction of supernatant, the platelets were resuspended in (Citrate-Phosphate-Dextrose anticoagulant) CPD Tyrode's solution or CPD-plasma at a final volume of 60 ml in P1-146 (plastic) bags (a trademark of Fenwall Company, Deerfield, Ill. 60015). The composition of the CPD-Tyrode's balanced salt solution is given in Table 1. These concentrates were stored at 22° C. in a horizontal shaker for testing after 3 days.
Platelet Aggregation: Aliquots from the platelet concentrates were diluted in pooled plasma containing CPD to a final concentration of 3×108 platelets/μl. After incubating for one hour at 37° the platelet suspensions were aggregated by addition of one stimulus or simultaneous addition of pairs of stimuli. The stimuli and concentrations used were adenosine diphosphate (ADP) at 10-5 M, epinephrine at 5×10-5 M, collagen at 2.4 μg/ml, arachidonic acid at 10-4 M, and calcium ionophore A23187 at 5×10-6 M. All these are final concentrations in the platelet suspensions.
The results for the platelets washed and resuspended in CPD-Tyrode's (Table 2) and CPD-plasma (Table 3) and for unwashed normal platelet concentrates (Table 4) are presented. The reported values are means and standard errors of at least three determinations except for those aggregations using arachidonate. The platelets stored in CPD-Tyrode's had slightly reduced aggregation responses when compared to the two control preparations stored in CPD-plasma. All three preparations lost the ability to aggregate to collagen, epinephrine or ADP while retaining aggregation response to pairs of stimuli or ionophore. The response to all three preparations were identical when tested before storage, indicating the washing procedure did not acutely alter the platelets (data not shown).
Preparation of Platelet Concentrates: Platelet concentrates were prepared by the normal centrifugation procedure of 3000 g for 5.5 minutes (no ACD was added). The plasma was extracted and the platelets resuspended in CPD-Tyrode's-phosphate solution, CPD-Tyrode's-Histidine (see Table 1 for recipes) or CPD-plasma at a final volume of 60 ml in PL 145 bags. These concentrates were stored at 22° C. in a horizontal shaker for testing after 3 days.
Platelet Aggregation: All aggregations were performed as in Series A.
The results for the platelets washed and resuspended in CPD-Tyrode's-phosphate (Table 5), and CPD-Tyrode's-Histidine (Table 6) and for unwashed normal platelet concentrates (Table 4) are presented and show values equal to or better than for platelets stored in the usual way in plasma. The reported values are means and standard errors of at least three determinations except for those aggregations using arachidonate. There was no difference between the platelets stored in CPD-Tyrode's-Histidine, CPD-Tyrode's-phosphate and the preparations stored in CPD-plasma. As in Series A, all three preparations lost the ability to aggregate to collagen, epinephrine or ADP while retaining aggregation response to pairs to stimuli or ionophore. The responses of all three preparations were identical when tested before storage, indicating the washing procedure did not significantly alter the platelets (data not shown).
TABLE 1______________________________________Composition of Some Artificial Mediums Used CPD- CPD-Tyrode's- CPD-Tyrode's- Tyrode's Phosphate Histidine______________________________________NaCl 120 mM 102 mM 102 mMKCl 2.4 mM 2.4 mM 2.4 mMNaHCO3 22.0 mM 10.0 mM 10.0 mMNaH2 PO4 0.4 mM 22.0 mM --CaCl2 1.8 mM 1.8 mM 1.8 mMMgCl2 0.9 mM 0.9 mM 0.9 mMGlucose 22.0 mM 22.0 mM 22.0 mMCitrate 1.0 mM 1.9 mM 1.9 mMTrisodium 10.8 mM 10.8 mM 10.8 mMCitrateNa2 HPO4 1.9 mM 1.9 mM --Histindine -- -- 22.0 mMpH 7.4 mM 7.4 mM 7.4 mMOsmolarity 298 mOsm 303 mOsm 313 mOsm______________________________________
TABLE 2______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22° C. for 72 hours in CPD-Tyrode's. First StimulusSecond Arach-Stimulus Saline ADP Epinephrine Collagen idonate______________________________________Saline 0ADP 5(2)*Epinephrine 2(3) 24(8)Collagen 1(2) 26(2) 22(18)Arachidonate 18(5) -- 34 --Ionophore 31(8) 29(8) 27(7) 31(9) --______________________________________ *mean (S.E.) of at least 3 determinations except for aggregations using arachidonate
TABLE 3______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22° C. for 72 hours in CPD-Plasma. First StimulusSecond Arach-Stimulus Saline ADP Epinephrine Collagen idonate______________________________________Saline 0ADP 8(5)*Epinephrine 1(1) 40(4)Collagen 2(2) 43(3) 47(6)Arachidonate 21(2) 48 46 --Ionophore 40(2) 45(6) 40(4) 47(10) 46______________________________________ *mean (S.E.) of at least 3 determintions except for aggregations using arachidonate
TABLE 4______________________________________Percent Platelet Aggregation After Storage of UnwashedPlatelets at 22° C. for 72 hours in CPD-Plasma First StimulusSecond Arach-Stimulus Saline ADP Epinephrine Collagen idonate______________________________________Saline 0ADP 14(5)*Epinephrine 0(1) 40(2)Collagen 2(1) 43(2) 41(2)Arachidonate 27(3) 44(2) 43(5) --Ionophore 47(5) 46(2) 39(2) 46(2) 44______________________________________ *mean (S.E.) of at least 7 determinations except for aggregations using arachidonate which are means of 3 determinations.
TABLE 5______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22° C. for 72 hours in CPD-Tyrode's-Phosphate. First StimulusSecond Arach-Stimulus Saline ADP Epinephrine Collagen idonate______________________________________Saline 0ADP 7Epinephrine 0 38Collagen 2 47 41Arachidonate 28 40 39 38*Ionophore 40 45 42 46 38*______________________________________
TABLE 6______________________________________Percent Platelet Aggregation After Storage of Washed Plateletsat 22° C. for 72 Hours in CPD-Tyrode's-Histidine. First StimulusSecond Arach-Stimulus Saline ADP Epinephrine Collagen idonate______________________________________Saline 0ADP 11Epinephrine 1 35Collagen 5 43 33Arachidonate 24* 42* 38* 33*Ionophore + 48 37 43 30*A23187______________________________________ *mean (S.E.) of at least 3 determinations except for aggregation using arachidonate + 2 experiments gave no aggregation with ionophore A23187 while one gave 36% aggregation. Normal platelet aggregation to ionophore A23187 were found in CPDTyrod' sPhosphate.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2786014 *||Sep 10, 1952||Mar 19, 1957||James L Tullis||Platelet preservation|
|US3629071 *||Feb 10, 1970||Dec 21, 1971||Upjohn Co||Storage-stable hemostatic transfusion suspensions of blood platelets, glucose, magnesium chloride and certain prostaglandins|
|US3729947 *||Dec 4, 1970||May 1, 1973||Alza Corp||Process for storing blood platelets|
|US3735005 *||Aug 19, 1970||May 22, 1973||Alza Corp||Method for preparing a viable platelet concentrate|
|US3753357 *||Dec 14, 1970||Aug 21, 1973||Ovitron Res Corp||Method and apparatus for the preservation of cells and tissues|
|US3814687 *||Jun 1, 1973||Jun 4, 1974||Honeywell Inc||Blood platelet separation|
|US3850174 *||Mar 14, 1973||Nov 26, 1974||Becton Dickinson Co||Plasma separator assembly|
|US4014993 *||Nov 17, 1975||Mar 29, 1977||The Upjohn Company||Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds|
|US4061537 *||Jul 16, 1976||Dec 6, 1977||Behringwerke Aktiengesellschaft||Polyionic isotonic salt solution|
|US4148879 *||Dec 23, 1977||Apr 10, 1979||Nelson Research & Development Company||Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters|
|US4152208 *||Dec 6, 1977||May 1, 1979||Hoffmann-La Roche Inc.||Stabilized leucocytes|
|US4267269 *||Feb 5, 1980||May 12, 1981||Baxter Travenol Laboratories, Inc.||Red cell storage solution|
|US4269718 *||May 5, 1980||May 26, 1981||The Institutes Of Medical Sciences||Process and device for centrifugal separation of platelets|
|US4387031 *||Jul 20, 1981||Jun 7, 1983||Luigi Prandi||Compositions able to separate the erythrocytes from the serum or plasma in blood analysis samples, and the method which uses them|
|US4390619 *||Sep 28, 1981||Jun 28, 1983||James Clifford Haight||Leukocyte or platelet storage using ion-exchange resins|
|US4405719 *||May 29, 1981||Sep 20, 1983||Coulter Electronics, Inc.||Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures|
|US4455299 *||Nov 20, 1981||Jun 19, 1984||Baxter Travenol Laboratories, Inc.||Storage of blood platelets|
|GB1014712A *||Title not available|
|GB1283273A *||Title not available|
|1||Abrahamsen, A. F., "A Modification of the Technique for 51 Cr-Labelling of Blood Platelets Giving Increased Circulating Platelet Radioactivity", Scand. J. Haemat. (1968), vol. 5, pp. 53-63.|
|2||*||Abrahamsen, A. F., A Modification of the Technique for 51 Cr Labelling of Blood Platelets Giving Increased Circulating Platelet Radioactivity , Scand. J. Haemat. (1968), vol. 5, pp. 53 63.|
|3||Adams, G. A. et al., "Serotonin Uptake by Stored Platelets", Thrombosis Research, (1982), vol. 28, pp. 281-284.|
|4||*||Adams, G. A. et al., Serotonin Uptake by Stored Platelets , Thrombosis Research, (1982), vol. 28, pp. 281 284.|
|5||Browdie, P. et al., "Stroma-Free Hemoglobin--Simplified Preparation and In Vivo and In Vitro Effects on Coagulation in Rabbits", The American Journal of Surgery, (1975), vol. 129, pp. 365-368.|
|6||*||Browdie, P. et al., Stroma Free Hemoglobin Simplified Preparation and In Vivo and In Vitro Effects on Coagulation in Rabbits , The American Journal of Surgery, (1975), vol. 129, pp. 365 368.|
|7||*||CA 77:59601q B. L. Tranum et al.: In vivo Survival of Platelets Prepared in CPD Anticoagulant, Transfusion, (1972), 12(3):168 74.|
|8||CA 77:59601q--B. L. Tranum et al.: "In vivo Survival of Platelets Prepared in CPD Anticoagulant," Transfusion, (1972), 12(3):168-74.|
|9||*||CA 94:448 728 E. P. Scott et al.: Viability and Function of Platelet Concentrates Stored in CPD Adenine (CPDA 1) , Transfusion, (1980), 20(J):489 97.|
|10||CA 94:448 728--E. P. Scott et al.: "Viability and Function of Platelet Concentrates Stored in CPD-Adenine (CPDA-1)", Transfusion, (1980), 20(J):489-97.|
|11||*||Chemical Abstracts 94:52751f, vol. 94, p. 356, (1981).|
|12||*||Definition of Ringer s Injection, Ringer s Solution, Lactated Ringer s Injection, Anticoagulant Sodium Citrate Solution, Anticoagulant Acid and Citrate Dextrose Solution.|
|13||Definition of Ringer's Injection, Ringer's Solution, Lactated Ringer's Injection, Anticoagulant Sodium Citrate Solution, Anticoagulant Acid and Citrate Dextrose Solution.|
|14||Holme, S. et al., "Comparative Measurements of Platelet Size by Coulter Counter, Microscopy of Blood Smears, and Light-Transmission Studies", J. Lab. Clin. Med., (1981), vol. 97, No. 5, pp. 610-622.|
|15||Holme, S. et al., "Platelet Storage at 22° C.: Effect of Type of Agitation on Morphology, Viability, and Function In Vitro", Blood, (1978), vol. 52, No. 2, pp. 425-435.|
|16||*||Holme, S. et al., Comparative Measurements of Platelet Size by Coulter Counter, Microscopy of Blood Smears, and Light Transmission Studies , J. Lab. Clin. Med., (1981), vol. 97, No. 5, pp. 610 622.|
|17||*||Holme, S. et al., Platelet Storage at 22 C.: Effect of Type of Agitation on Morphology, Viability, and Function In Vitro , Blood, (1978), vol. 52, No. 2, pp. 425 435.|
|18||Kuchler, R. J., "Biochemical Methods in Cell Culture and Virology", (1977), published by Dowden, Hutchinson & Ross, Inc., pp. 83-90.|
|19||*||Kuchler, R. J., Biochemical Methods in Cell Culture and Virology , (1977), published by Dowden, Hutchinson & Ross, Inc., pp. 83 90.|
|20||Kunicki, T. J. et al., "A Study of Variables Affecting the Quality of Platelets Stored at `Room Temperature`", Transfusion, (1975), vol. 15, No. 5, pp. 414-421.|
|21||*||Kunicki, T. J. et al., A Study of Variables Affecting the Quality of Platelets Stored at Room Temperature , Transfusion, (1975), vol. 15, No. 5, pp. 414 421.|
|22||Lazzlo, J., "Energy Metabolism of Human Leukemic Lymphocytes and Granulocytes", Blood, (1967), vol. 30, No. 2, pp. 151-167.|
|23||*||Lazzlo, J., Energy Metabolism of Human Leukemic Lymphocytes and Granulocytes , Blood, (1967), vol. 30, No. 2, pp. 151 167.|
|24||*||Matsumoto Chem. Abst., vol. 91, (1979), p. 136,650y.|
|25||Matsumoto--Chem. Abst., vol. 91, (1979), p. 136,650y.|
|26||Murphy, S. et al., "Platelet Size and Kinetics in Hereditary and Acquired Thrombocytopenia", New England Journal of Medicine, (1972), vol. 286, pp. 499-504.|
|27||Murphy, S. et al., "Platelet Storage at 22° C.: Role of Gas Transport Across Plastic Containers in Maintenance of Viability", Blood, (1975), vol. 46, No. 2, pp. 209-218.|
|28||Murphy, S. et al., "Storage of Platelet Concentrates at 22° C.", Blood, (1970), vol. 35, No. 4, pp. 549-557.|
|29||*||Murphy, S. et al., Platelet Size and Kinetics in Hereditary and Acquired Thrombocytopenia , New England Journal of Medicine, (1972), vol. 286, pp. 499 504.|
|30||*||Murphy, S. et al., Platelet Storage at 22 C.: Role of Gas Transport Across Plastic Containers in Maintenance of Viability , Blood, (1975), vol. 46, No. 2, pp. 209 218.|
|31||*||Murphy, S. et al., Storage of Platelet Concentrates at 22 C. , Blood, (1970), vol. 35, No. 4, pp. 549 557.|
|32||Murphy, S., "Platelet Transfusion", Prog. Hemostasis Thromb., (1976), vol. 3, pp. 289-310.|
|33||Murphy, S., "The Preparation and Storage of Platelets for Transfusions", Treatment of Bleeding Disorders by Mammen, Barnhart, Lusher and Walsh, (1980), pp. 303-313.|
|34||*||Murphy, S., Platelet Transfusion , Prog. Hemostasis Thromb., (1976), vol. 3, pp. 289 310.|
|35||*||Murphy, S., The Preparation and Storage of Platelets for Transfusions , Treatment of Bleeding Disorders by Mammen, Barnhart, Lusher and Walsh, (1980), pp. 303 313.|
|36||Reitzer, L. J. et al., "Evidence That Glutamine, Not Sugar is the Major Energy Source for Cultured HeLa Cells", J. Biol. Chem., (1979), vol. 254, No. 8, pp. 2669-2676.|
|37||Reitzer, L. J. et al., "The Pentose Cycle", J. Biol. Chem., (1980), vol. 255, No. 12, pp. 5616-5626.|
|38||*||Reitzer, L. J. et al., Evidence That Glutamine, Not Sugar is the Major Energy Source for Cultured HeLa Cells , J. Biol. Chem., (1979), vol. 254, No. 8, pp. 2669 2676.|
|39||*||Reitzer, L. J. et al., The Pentose Cycle , J. Biol. Chem., (1980), vol. 255, No. 12, pp. 5616 5626.|
|40||Rock, G. A. et al., "Storage of Platelets Collected by Apheresis", Transfusion, (1983), vol. 23, No. 2, pp. 99-105.|
|41||*||Rock, G. A. et al., Storage of Platelets Collected by Apheresis , Transfusion, (1983), vol. 23, No. 2, pp. 99 105.|
|42||Rock, G. et al., "Platelet Storage: An Assessment of the Requirements for Plasma and Oxygen", Transfusion, (1981), vol. 21, No. 2, pp. 167-177.|
|43||Rock, G. et al., "Storage of Platelets Obtained by Apheresis Techniques", Plasma Ther. Transfrs. Technol., (1982), vol. 3, pp. 305-308.|
|44||*||Rock, G. et al., Platelet Storage: An Assessment of the Requirements for Plasma and Oxygen , Transfusion, (1981), vol. 21, No. 2, pp. 167 177.|
|45||*||Rock, G. et al., Storage of Platelets Obtained by Apheresis Techniques , Plasma Ther. Transfrs. Technol., (1982), vol. 3, pp. 305 308.|
|46||*||Sivertsen Chem. Abst., vol. 77, (1972), p. 73201r.|
|47||Sivertsen--Chem. Abst., vol. 77, (1972), p. 73201r.|
|48||Tegos, C. et al., "Platelet Glycolysis in Platelet Storage--III; The Inability of Platelets to Utilize Exogenous Citrate".|
|49||*||Tegos, C. et al., Platelet Glycolysis in Platelet Storage III; The Inability of Platelets to Utilize Exogenous Citrate .|
|50||Wise, B. M. et al., "The Continuous Growth of Vertebrate Cells in the Absence of Sugar", J. Biol. Chem., (1981), vol. 256, No. 15, pp. 7812-7819.|
|51||*||Wise, B. M. et al., The Continuous Growth of Vertebrate Cells in the Absence of Sugar , J. Biol. Chem., (1981), vol. 256, No. 15, pp. 7812 7819.|
|52||Wong, S. C. et al., "The Effect of Adenine on Platelet Storage", Transfusion, (1982), vol. 22, No. 4, pp. 283-287.|
|53||*||Wong, S. C. et al., The Effect of Adenine on Platelet Storage , Transfusion, (1982), vol. 22, No. 4, pp. 283 287.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5147776 *||Feb 26, 1990||Sep 15, 1992||University Of Iowa Research Foundation||Use of 2,5-anhydromannitol for control of pH during blood storage|
|US5234808 *||Oct 30, 1991||Aug 10, 1993||Thomas Jefferson University||Acetate addition to platelets stored in plasma|
|US5344752 *||Apr 7, 1993||Sep 6, 1994||Thomas Jefferson University||Plasma-based platelet concentrate preparations|
|US5376524 *||Dec 1, 1992||Dec 27, 1994||Thomas Jefferson University||Platelet storage medium containing acetate and phosphate|
|US5378601 *||Jul 24, 1992||Jan 3, 1995||Montefiore Medical Center||Method of preserving platelets with apyrase and an antioxidant|
|US5459030 *||Jun 2, 1993||Oct 17, 1995||Steritech, Inc.||Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen|
|US5466573 *||Aug 5, 1994||Nov 14, 1995||Thomas Jefferson University||Platelet storage method in a medium containing acetate and phosphate|
|US5474891 *||Jun 16, 1994||Dec 12, 1995||Thomas Jefferson University||Plasma-based platelet concentrate preparations with additive|
|US5482828 *||Mar 7, 1994||Jan 9, 1996||Steritech, Inc.||Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen|
|US5569579 *||Mar 17, 1994||Oct 29, 1996||Thomas Jefferson University||Synthetic-based platelet storage media|
|US5589395 *||Apr 15, 1993||Dec 31, 1996||Behringwerke Aktiengesellschaft||Method for stabilizing annexins|
|US5618662 *||Jan 21, 1994||Apr 8, 1997||Cerus Corporation||Intravenous administration of psoralen|
|US5709991 *||Jun 7, 1995||Jan 20, 1998||Cerus Corporation||Proralen inactivation of microorganisms and psoralen removal|
|US5906915 *||Oct 31, 1996||May 25, 1999||Baxter International Inc.||Method for storing red cells using reduced citrate anticoagulant and a solution containing sodium, citrate, phosphate, adenine and mannitol|
|US6251580||Jan 29, 1999||Jun 26, 2001||Lily Lin||Synthetic media for blood components|
|US6258577||Jul 21, 1998||Jul 10, 2001||Gambro, Inc.||Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers|
|US6268120||Oct 19, 1999||Jul 31, 2001||Gambro, Inc.||Isoalloxazine derivatives to neutralize biological contaminants|
|US6277337||Jul 20, 1999||Aug 21, 2001||Gambro, Inc.||Method and apparatus for inactivation of biological contaminants using photosensitizers|
|US6277556||Dec 17, 1998||Aug 21, 2001||Baxter International Inc.||Controlling donor blood characteristics|
|US6326197||Jan 24, 2000||Dec 4, 2001||Baxter International Inc.||Platelet suspensions and methods for resuspending platelets|
|US6413713 *||Oct 30, 1998||Jul 2, 2002||Hyperbaric Systems||Method for preserving blood platelets|
|US6548241||Nov 28, 2000||Apr 15, 2003||Gambro, Inc.||Storage solution containing photosensitizer for inactivation of biological contaminants|
|US6566046||Dec 7, 2000||May 20, 2003||Baxter International Inc.||Synthetic media for blood components|
|US6613566||Oct 26, 2001||Sep 2, 2003||Baxter International Inc.||Platelet suspensions and methods for resuspending platelets|
|US6828323||Feb 5, 2001||Dec 7, 2004||Gambro, Inc.||Isoalloxazine derivatives to neutralize biological contaminants|
|US6866992 *||Apr 14, 2003||Mar 15, 2005||Baxter International Inc.||Synthetic platelet storage media formulation|
|US7029839||Apr 22, 2004||Apr 18, 2006||Human Biosystems||Methods and solutions for storing donor organs|
|US7049110||Feb 3, 2003||May 23, 2006||Gambro, Inc.||Inactivation of West Nile virus and malaria using photosensitizers|
|US7094378||Jun 15, 2000||Aug 22, 2006||Gambro, Inc.||Method and apparatus for inactivation of biological contaminants using photosensitizers|
|US7183045||Apr 24, 2003||Feb 27, 2007||Gambro Inc.||Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution|
|US7202020||Jun 9, 2004||Apr 10, 2007||Human Biosystems||Compositions, methods and apparatuses for preserving platelets|
|US7220747||May 6, 2003||May 22, 2007||Gambro, Inc.||Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer|
|US7498156||Jun 15, 2005||Mar 3, 2009||Caridianbct Biotechnologies, Llc||Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components|
|US7648699||Aug 31, 2006||Jan 19, 2010||Caridianbct Biotechnologies, Llc||Preventing transfusion related complications in a recipient of a blood transfusion|
|US7892535||Dec 3, 2009||Feb 22, 2011||Caridianbct Biotechnologies, Llc||Preventing transfusion related complications in a recipient of a blood transfusion|
|US7901673||Aug 25, 2003||Mar 8, 2011||Caridianbct Biotechnologies, Llc||Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light|
|US7985588||Oct 31, 2007||Jul 26, 2011||Caridianbct Biotechnologies, Llc||Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light|
|US8679736||Dec 17, 2009||Mar 25, 2014||Terumo Bct Biotechnologies, Llc||Removal of adenine during a pathogen reduction process in whole blood or red blood cells by dilution|
|US8835104||Dec 18, 2008||Sep 16, 2014||Fenwal, Inc.||Medium and methods for the storage of platelets|
|US9044523||Aug 17, 2007||Jun 2, 2015||Terumo Bct, Inc.||Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light|
|US9168281||Mar 9, 2012||Oct 27, 2015||Charles E. Worden, SR.||Kit for treating a wound|
|US9402866||Apr 6, 2012||Aug 2, 2016||Fenwal, Inc.||Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates|
|US20030194806 *||Apr 14, 2003||Oct 16, 2003||Lily Lin||Synthetic media for blood components|
|US20030201160 *||Apr 24, 2003||Oct 30, 2003||Gambro, Inc.||Removal of adenine during a process of pathogen reducing blood and blood components|
|US20040081956 *||Aug 25, 2003||Apr 29, 2004||Gambro, Inc.||Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light|
|US20040223957 *||Jun 9, 2004||Nov 11, 2004||Lucas David O.||Compositions, methods and apparatuses for preserving platelets|
|US20050019917 *||Apr 22, 2004||Jan 27, 2005||Human Biosystems||Methods and solutions for storing donor organs|
|US20050282143 *||Jun 15, 2005||Dec 22, 2005||Gambro, Inc.||Use of visible light at wavelengths of 500 nm and higher to pathogen reduce blood and blood components|
|US20060121438 *||Feb 16, 2006||Jun 8, 2006||Human Biosystems||Methods and solutions for storing donor organs|
|US20070098697 *||Aug 31, 2006||May 3, 2007||Navigant Biotechnologies, Inc.||Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion|
|US20070099170 *||Dec 1, 2006||May 3, 2007||Navigant Biotechnologies, Inc.||Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate|
|US20070148630 *||Jan 18, 2007||Jun 28, 2007||Gambro, Inc.||Removal of Adenine During a Pathogen Reduction Process in Whole Blood or Red Blood Cells by Dilution|
|US20080107636 *||Oct 31, 2007||May 8, 2008||Navigant Biotechnologies, Llc||Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light|
|US20080299538 *||Jul 30, 2008||Dec 4, 2008||Caridianbct Biotechnologies, Llc||Pathogen Inactivation of Whole Blood|
|US20090023130 *||Aug 13, 2008||Jan 22, 2009||Caridianbct Biotechnologies, Llc||Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light|
|US20090191537 *||Dec 18, 2008||Jul 30, 2009||Veronique Mayaudon||Medium and methods for the storage of platelets|
|US20100080781 *||Dec 3, 2009||Apr 1, 2010||Caridianbct Biotechnologies, Llc||Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion|
|US20100089840 *||Dec 17, 2009||Apr 15, 2010||Caridianbct Biotechnologies, Llc||Removal of Adenine During A Pathogen Reduction Process in Whole Blood or Red Blood Cells by Dilution|
|EP0510185A1 *||Oct 30, 1991||Oct 28, 1992||Baxter Int||Blood platelet storage medium.|
|EP0510185B1 *||Oct 30, 1991||Dec 11, 1996||Baxter International Inc.||Blood platelet storage medium|
|WO1992008349A1 *||Oct 30, 1991||May 29, 1992||Baxter International Inc.||Blood platelet storage medium|
|WO1994002015A1 *||Jul 2, 1993||Feb 3, 1994||Montefiore Medical Center||Method of preserving platelets|
|WO1998056247A1 *||May 15, 1998||Dec 17, 1998||Baxter International Inc.||Platelet suspensions and methods for resuspending platelets|
|U.S. Classification||424/93.72, 435/2|
|International Classification||A61K35/14, A01N1/02|
|Cooperative Classification||A61K35/19, A01N1/02, A01N1/0226|
|European Classification||A61K35/14, A01N1/02, A01N1/02C2P|
|May 8, 1986||AS||Assignment|
Owner name: ROCK, GAIL A., 270 SANDRIDGE RD., ROCKCLIFFE PARK,
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ADAMS, GEORGE A.;REEL/FRAME:004969/0252
Effective date: 19860502
|Sep 30, 1991||FPAY||Fee payment|
Year of fee payment: 8
|Oct 31, 1995||FPAY||Fee payment|
Year of fee payment: 12